Breaking

Cartel connection: Hezbollah and Iran exploit Maduro’s Venezuela for cocaine cash
Trump nominees pile up as GOP weighs rule shift once floated by Democrats
US-backed Gaza aid group slams Doctors Without Borders, accuses it of spreading ‘false’ claims
With friends like these pushing to dismantle Trump’s Middle East peace deal, who needs enemies?
Trump delivers ultimatum to Hamas: hostages home or pay the consequences
Trump delivers ultimatum to Hamas: Accept deal and release hostages or pay the consequences
Operational Update
MIKE DAVIS: Impeachment time for Trump-hating renegade Judge Boasberg

Home
Features
- View All On Demos
Buy Now
Search for:

Investing

Completion of preclinical data package for RAD 402

December 10, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced Completion of preclinical data package for RAD 402

Download the PDF here.

This post appeared first on investingnews.com

1

admin

Website

Related Posts

Operational Update

September 8, 2025

Québec Communities Vote “No” to La Loutre Graphite Mine

September 6, 2025

Purepoint Uranium Closes Final Tranche of $6 Million Private Placement

September 6, 2025

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (535)
- Investing (1,920)
- Politics (2,291)
- Stocks (666)

Disclaimer: 2morrowgrowth.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 2morrowgrowth.com | All Rights Reserved

Top

Type above and press Enter to search. Press Esc to cancel.